Current status of biomarker research in neurology

EPMA Journal

Volumn 7, Issue 1, 2016, Pages

  Polivka, Jiri ^a,b   Krakorova, Kristyna ^a,b   Peterka, Marek ^a,b   Topolcan, Ondrej ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Faculty Hospital   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer's disease; Biomarker; Multiple sclerosis; Neuro oncology; Parkinson's disease; Personalized medicine; Predictive preventive personalized medicine; Stroke

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; CYTOCHROME P450 2C19; D DIMER; FIBRINOGEN; FIBRONECTIN; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MALONALDEHYDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MYELIN BASIC PROTEIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURON SPECIFIC ENOLASE; PROTEIN S100B; TAU PROTEIN; THROMBOMODULIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VON WILLEBRAND FACTOR;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CHROMOSOME 19Q; CHROMOSOME 1P; GLIOBLASTOMA; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGY; OLIGODENDROGLIOMA; PARKINSON DISEASE; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW;

EID: 84977107255     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1186/s13167-016-0063-5     Document Type: Review

References (157)

1. Gottlieb S. Personalised medicine comes a step closer for asthma. BMJ. 2000;321:724.
2. Nebert DW, Zhang G, Vesell ES. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons. Future Directions Drug Metab Rev. 2008;40:187-224.
3. Golubnitschaja O, Costigliola V, EPMA. General report & recommendations in predictive, preventive and personalised medicine 2012: white paper of the European Association for Predictive, Preventive and Personalised Medicine. EPMA J. 2012;3:14.
4. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114:97-109.
5. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98-110.
6. Polivka Jr J, Polivka J, Rohan V, Topolcan O, Ferda J. New molecularly targeted therapies for glioblastoma multiforme. Anticancer Res. 2012;32:2935-46.
7. Polivka J, Pesta M, Janku F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn. 2015;15:1631-44.
8. Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR. Glioblastoma care in the elderly. Cancer. 2016;122:189-97.
9. Cabrini G, Fabbri E, Lo Nigro C, Dechecchi MC, Gambari R. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review). Int J Oncol. 2015;47:417-28.
10. Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R. Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol. 2013;14:e370-9.
11. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997-1003.
12. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, et al. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro Oncol. 2010;12:116-21.
13. Raimundo N, Baysal BE, Shadel GS. Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med. 2011;17:641-9.
14. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807-12.
15. Yan H, Parsons DW, Jin G, Mclendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360:765-73.
16. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol. 2009;118:469-74.
17. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27:4150-4.
18. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707-18.
19. Polivka J, Polivka Jr J, Rohan V, Topolcan O. Glioblastoma multiforme-a review of pathogenesis, biomarkers and therapeutic perspectives. Cesk Slov Neurol N. 2013;76/109:575-83.
20. Polivka J, Polivka Jr J, Rohan V, Pesta M, Repik T, Pitule P, et al. Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in west bohemia. Biomed Res Int. 2014;2014:735659.
21. Xia L, Wu B, Fu Z, Feng F, Qiao E, Li Q, et al. Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies. Oncotarget. 2015;6:17354-65.
22. Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JWM, Boots-Sprenger SHE, et al. The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 2014;16:1263-73.
23. Polivka J, Polivka J, Rohan V, Topolcan O. New treatment paradigm for patients with anaplastic oligodendroglial tumors. Anticancer Res. 2014;34:1587-94.
24. Van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJB, Bernsen HJJA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. 2006;24:2715-22.
25. Kraus JA, Koopmann J, Kaskel P, Maintz D, Brandner S, Schramm J, et al. Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol. 1995;54:91-5.
26. Cahill DP, Louis DN, Cairncross JG. Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1. CNS Oncol. 2015;4:287-94.
27. Intergroup Radiation Therapy Oncology Group Trial 9402, Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. 2006;24:2707-14.
28. Van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM, Delattre J-Y, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31:344-50.
29. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 2013;31:337-43.
30. Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the World Health Organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3:95.
31. Killock D. CNS cancer: molecular classification of glioma. Nat Rev Clin Oncol. 2015;12:502.
32. Polivka J, Polivka J, Repik T, Rohan V, Hes O, Topolcan O. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma. Anticancer Res. 2016;36:471-6.
33. Szymanski FM, Lip GYH, Filipiak KJ, Platek AE, Hrynkiewicz-Szymanska A, Opolski G. Stroke Risk Factors Beyond the CHA2DS2-VASc Score: Can We Improve Our Identification of "High Stroke Risk" Patients With Atrial Fibrillation? Am J Cardiol. 2015;116:1781-8.
34. Senn R, Elkind MSV, Montaner J, Christ-Crain M, Katan M. Potential role of blood biomarkers in the management of nontraumatic intracerebral hemorrhage. Cerebrovasc Disz. 2014;38:395-409.
35. Jickling GC, Sharp FR. Biomarker panels in ischemic stroke. Stroke. 2015;46:915-20.
36. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009;111:483-95.
37. Kernagis DN, Laskowitz DT. Evolving role of biomarkers in acute cerebrovascular disease. Ann Neurol. 2012;71:289-303.
38. Ren C, Kobeissy F, Alawieh A, Li N, Li N, Zibara K, et al. Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients. Sci Rep. 2016;6:24588.
39. Turner RJ, Sharp FR. Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke. Front Cell Neurosci. 2016;10:56.
40. Montaner J. Blood biomarkers to guide stroke thrombolysis. Front Biosci (Elite Ed). 2009;1:200-8.
41. Bettermann K. Biomarkers for stroke: in search of fingerprints. J Stroke Cerebrovasc Dis. 2011;20:173-6.
42. Whiteley W, Tseng MC, Sandercock P. Blood biomarkers in the diagnosis of ischemic stroke: a systematic review. Stroke. 2008;39:2902-9.
43. Sharp FR, Jickling GC, Stamova B, Tian Y, Zhan X, Liu D, et al. Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J Cereb Blood Flow Metab. 2011;31:1513-31.
44. Di Stefano V, Zaccagnini G, Capogrossi MC, Martelli F. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vasc Pharmacol. 2011;55:111-8.
45. Li M, Zhang J. Circulating MicroRNAs: Potential and Emerging Biomarkers for Diagnosis of Cardiovascular and Cerebrovascular Diseases. Biomed Res Int. 2015;2015:730535.
46. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-62.
47. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93.
48. Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002;287:1690-8.
49. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med. 2008;359:789-99.
50. Mandel SA, Morelli M, Halperin I, Korczyn AD. Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J. 2010;1:273-92.
51. Golubnitschaja O. Neurodegeneration: accelerated ageing or inadequate healthcare? EPMA J. 2010;1:211-5.
52. Qiu C, Kivipelto M, von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci. 2009;11:111-28.
53. Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer's disease therapeutics. Front Neurol. 2015;6:186.
54. Noelker C, Hampel H, Dodel R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases. Mol Diagn Ther. 2011;15:83-102.
55. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol. 2010;6:131-44.
56. Rosén C, Hansson O, Blennow K, Zetterberg H. Fluid biomarkers in Alzheimer's disease - current concepts. Mol Neurodegener. 2013;8:20.
57. Blennow K, Zetterberg H. The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events. Front Neurosci. 2015;9:345.
58. Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 2008;4:38-48.
59. Du Y, Dodel R, Hampel H, Buerger K, Lin S, Eastwood B, et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology. 2001;57:801-5.
60. Hyman BT, Smith C, Buldyrev I, Whelan C, Brown H, Tang MX, et al. Autoantibodies to amyloid-beta and Alzheimer's disease. Ann Neurol. 2001;49:808-10.
61. Moir RD, Tseitlin KA, Soscia S, Hyman BT, Irizarry MC, Tanzi RE. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem. 2005;280:17458-63.
62. Bush AI, Martins RN, Rumble B, Moir R, Fuller S, Milward E, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990;265:15977-83.
63. Borroni B, Colciaghi F, Corsini P, Akkawi N, Rozzini L, Del Zotto E, et al. Early stages of probable Alzheimer disease are associated with changes in platelet amyloid precursor protein forms. Neurol Sci. 2002;23:207-10.
64. Padovani A, Borroni B, Colciaghi F, Pettenati C, Cottini E, Agosti C, et al. Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease. Arch Neurol. 2002;59:71-5.
65. Raber J, Huang Y, Ashford JW. ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging. 2004;25:641-50.
66. Tiraboschi P, Hansen LA, Masliah E, Alford M, Thal LJ, Corey-Bloom J. Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease. Neurology. 2004;62:1977-83.
67. He S, Liu D, Wang S, Xia Y. Expression of apolipoprotein E in Alzheimer's disease and its significance. Zhonghua Bing Li Xue Za Zhi. 2005;34:556-60.
68. Evans RM, Emsley CL, Gao S, Sahota A, Hall KS, Farlow MR, et al. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology. 2000;54:240-2.
69. Papassotiropoulos A, Lütjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport. 2000;11:1959-62.
70. Sato Y, Suzuki I, Nakamura T, Bernier F, Aoshima K, Oda Y. Identification of a new plasma biomarker of Alzheimer's disease using metabolomics technology. J Lipid Res. 2012;53:567-76.
71. Li F-J, Shen L, Ji H-F. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer's disease: a meta-analysis. J Alzheimers Dis. 2012;31:253-8.
72. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med. 1997;336:1216-22.
73. Mangialasche F, Solomon A, Kåreholt I, Hooshmand B, Cecchetti R, Fratiglioni L, et al. Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol. 2013;48:1428-35.
74. Lu'o'ng KVQ, Nguyen LTH. The role of vitamin D in Alzheimer's disease: possible genetic and cell signaling mechanisms. Am J Alzheimers Dis Other Demen. 2013;28:126-36.
75. Praticò D, Clark CM, Liun F, Rokach J, Lee VY-M, Trojanowski JQ. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol. 2002;59:972-6.
76. Montine TJ, Quinn JF, Milatovic D, Silbert LC, Dang T, Sanchez S, et al. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann Neurol. 2002;52:175-9.
77. Dou C, Zhang J, Sun Y, Zhao X, Wu Q, Ji C, et al. The association of ACT-17 A/T polymorphism with Alzheimer's disease: a meta-analysis. Curr Alzheimer Res. 2013;10:63-71.
78. Zhang Jr J, Shi Sr S. A literature review of AD7c-ntp as a biomarker for Alzheimer's disease. Ann Indian Acad Neurol. 2013;16:307-9.
79. Fennema-Notestine C, Panizzon MS, Thompson WR, Chen C-H, Eyler LT, Fischl B, et al. Presence of ApoE ε4 allele associated with thinner frontal cortex in middle age. J Alzheimers Dis. 2011;26(Suppl 3):49-60.
80. Carmichael O, Xie J, Fletcher E, Singh B, DeCarli C. Alzheimer's Disease Neuroimaging Initiative. Localized hippocampus measures are associated with Alzheimer pathology and cognition independent of total hippocampal volume. Neurobiol Aging. 2012;33(1124):e31-41.
81. Sabuncu MR, Desikan RS, Sepulcre J, Yeo BTT, Liu H, Schmansky NJ, et al. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68:1040-8.
82. Mosconi L, Tsui W-H, De Santi S, Li J, Rusinek H, Convit A, et al. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology. 2005;64:1860-7.
83. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging. 2005;32:486-510.
84. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404-11.
85. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, Langois CM, et al. Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol. 2012;11:1057-65.
86. Schapira AHV. Recent developments in biomarkers in Parkinson disease. Curr Opin Neurol. 2013;26:395-400.
87. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain J Neurol. 1991;114(Pt 5):2283-301.
88. Ferrer I, López-Gonzalez I, Carmona M, Dalfó E, Pujol A, Martínez A. Neurochemistry and the non-motor aspects of PD. Neurobiol Dis. 2012;46:508-26.
89. Ferrer I. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. Parkinsons Dis. 2011;2011:708404.
90. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230-40.
91. Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, et al. Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain J Neurol. 2011;134:e178.
92. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, et al. Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med. 2012;4:121-20.
93. Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, et al. Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. Neurobiol Dis. 2015;80:29-41.
94. Im SY, Kim YE, Kim YJ. Genetics of progressive supranuclear palsy. J Mov Disord. 2015;8:122-9.
95. El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J. 2006;20:419-25.
96. Neff F, Wei X, Nölker C, Bacher M, Du Y, Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev. 2008;7:501-7.
97. Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167:90-5.
98. Scalzo P, Kümmer A, Bretas TL, Cardoso F, Teixeira AL. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. J Neurol. 2010;257:540-5.
99. Parker Jr WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26:719-23.
100. Mann VM, Cooper JM, Krige D, Daniel SE, Schapira AH, Marsden CD. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain J Neurol. 1992;115(Pt 2):333-42.
101. Götz ME, Gerstner A, Harth R, Dirr A, Janetzky B, Kuhn W, et al. Altered redox state of platelet coenzyme Q10 in Parkinson's disease. J Neural Transm (Vienna). 2000;107:41-8.
102. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65:716-23.
103. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol. 2011;69:655-63.
104. Verstraeten A, Theuns J, Van Broeckhoven C. Progress in unraveling the genetic etiology of Parkinson disease in a genomic era. Trends Genet. 2015;31:140-9.
105. Oeda T, Umemura A, Mori Y, Tomita S, Kohsaka M, Park K, et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging. 2015;36:3306-13.
106. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci. 2003;4:727-38.
107. Azuma R, Ishikawa K, Hirata K, Hashimoto Y, Takahashi M, Ishii K, et al. A novel mutation of PDE8B Gene in a Japanese family with autosomal-dominant striatal degeneration. Mov Disord. 2015;30:1964-7.
108. Sharma S, Moon CS, Khogali A, Haidous A, Chabenne A, Ojo C, et al. Biomarkers in Parkinson's disease (recent update). Neurochem Int. 2013;63:201-29.
109. Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WRW. Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson's disease. Mov Disord. 2007;22:382-6.
110. Wu G, Shen Y-J, Huang M-H, Xing Z, Liu Y, Chen J. Proton MR Spectroscopy for Monitoring Pathologic Changes in the Substantia Nigra and Globus Pallidus in Parkinson Disease. AJR Am J Roentgenol. 2016;206:385-9.
111. Brooks DJ. Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Mov Disord. 2009;24 Suppl 2:S742-7.
112. Garibotto V, Montandon ML, Viaud CT, Allaoua M, Assal F, Burkhard PR, et al. Regions of interest-based discriminant analysis of DaTSCAN SPECT and FDG-PET for the classification of dementia. Clin Nucl Med. 2013;38:e112-7.
113. Tripathi M, Tripathi M, Damle N, Kushwaha S, Jaimini A, D'Souza MM, et al. Differential diagnosis of neurodegenerative dementias using metabolic phenotypes on F-18 FDG PET/CT. Neuroradiol J. 2014;27:13-21.
114. Löhle M, Mende J, Wolz M, Beuthien-Baumann B, Oehme L, van den Hoff J, et al. Putaminal dopamine turnover in de novo Parkinson disease predicts later motor complications. Neurology. 2016;86:231-40.
115. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol. 2005;57:168-75.
116. Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, et al. [99mTc] TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology. 2005;64:1716-20.
117. Weintraub D, Newberg AB, Cary MS, Siderowf AD, Moberg PJ, Kleiner-Fisman G, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med. 2005;46:227-32.
118. Ramirez-Zamora A, Gee L, Boyd J, Biller J. Treatment of impulse control disorders in Parkinson's disease: Practical considerations and future directions. Expert Rev Neurother. 2016;16:389-99.
119. Nakum S, Cavanna AE. The prevalence and clinical characteristics of hypersexuality in patients with Parkinson's disease following dopaminergic therapy: A systematic literature review. Parkinsonism Relat Disord. 2016;25:10-6.
120. Wattjes MP, Rovira À, Miller D, Yousry TA, Sormani MP, de Stefano MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597-606.
121. Rovira À, Wattjes MP, Tintoré M, Tur C, Yousry TA, Sormani MP, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nat Rev Neurol. 2015;11:471-82.
122. Owens GP, Bennett JL, Lassmann H, O'Connor KC, Ritchie AM, Shearer A, et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009;65:639-49.
123. Mandrioli J, Sola P, Bedin R, Gambini M, Merelli E. A multifactorial prognostic index in multiple sclerosis. Cerebrospinal fluid IgM oligoclonal bands and clinical features to predict the evolution of the disease. J Neurol. 2008;255:1023-31.
124. Brettschneider J, Tumani H, Kiechle U, Muche R, Richards G, Lehmensiek V, et al. IgG antibodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS One. 2009;4:e7638.
125. Margaritella N, Mendozzi L, Garegnani M, Nemni R, Colicino E, Gilardi E, et al. Exploring the predictive value of the evoked potentials score in MS within an appropriate patient population: a hint for an early identification of benign MS? BMC Neurol. 2012;12:80.
126. Schlaeger R, D'Souza M, Schindler C, Grize L, Kappos L, Fuhr P. Combined evoked potentials as markers and predictors of disability in early multiple sclerosis. Clin Neurophysiol. 2012;123:406-10.
127. Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler. 2015;21:1013-24.
128. Tintore M, Rovira À, Río J, Otero-Romero S, Arrambide G, Tur C, et al. Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain J Neurol. 2015;138:1863-74.
129. Dörr J, Döring A, Paul F. Can we prevent or treat multiple sclerosis by individualised vitamin D supply? EPMA J. 2013;4:4.
130. Behrens JR, Rasche L, Gieß RM, Pfuhl C, Wakonig K, Freitag E, et al. Low 25-hydroxyvitamin D, but not the bioavailable fraction of 25-hydroxyvitamin D, is a risk factor for multiple sclerosis. Eur J Neurol. 2016;23:62-7.
131. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, et al. Effect of vitamin D on MS activity by disease-modifying therapy class. Neurol Neuroimmunol Neuroinflamm. 2015;2:e167.
132. Kimbrough DJ, Mealy MA, Simpson A, Levy M. Predictors of recurrence following an initial episode of transverse myelitis. Neurol Neuroimmunol Neuroinflamm. 2014;1:e4.
133. Sormani MP, Rio J, Tintorè M, Signori A, Li D, Cornelisse P, et al. Scoring treatment response in patients with relapsing multiple sclerosis. Mult Scler. 2013;19:605-12.
134. Río J, Castilló J, Rovira A, Tintoré M, Sastre-Garriga J, Horga A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler. 2009;15:848-53.
135. Stangel M, Penner IK, Kallmann BA, Lukas C, Kieseier BC. Towards the implementation of "no evidence of disease activity" in multiple sclerosis treatment: the multiple sclerosis decision model. Ther Adv Neurol Disord. 2015;8:3-13.
136. Dörr J, Paul F. The transition from first-line to second-line therapy in multiple sclerosis. Curr Treat Options Neurol. 2015;17:354.
137. Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, et al. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016;15(6):574-84.
138. Schneider E, Zimmermann H, Oberwahrenbrock T, Kaufhold F, Kadas EM, Petzold A, et al. Optical coherence tomography reveals distinct patterns of retinal damage in neuromyelitis optica and multiple sclerosis. PLoS One. 2013;8:e66151.
139. Bennett JL, de Seze J, Lana-Peixoto M, Palace J, Waldman A, Schippling S, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler. 2015;21:678-88.
140. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol. 2005;166:180-8.
141. Deisenhammer F, Mayringer I, Harvey J, Dilitz E, Gasse T, Stadlbauer D, et al. A comparative study of the relative bioavailability of different interferon beta preparations. Neurology. 2000;54:2055-60.
142. Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-91.
143. Bertolotto A, Gilli F, Sala A, Audano L, Castello A, Magliola U, et al. Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. J Immunol Methods. 2001;256:141-52.
144. Hesse D, Sellebjerg F, Sorensen PS. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity. Neurology. 2009;73:372-7.
145. Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Capobianco M, et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006;12:47-57.
146. Tian W, Zhu T, Zhong J, Liu X, Rao P, Segal BM, et al. Progressive decline in fractional anisotropy on serial DTI examinations of the corpus callosum: a putative marker of disease activity and progression in SPMS. Neuroradiology. 2012;54:287-97.
147. Brown RA, Narayanan S, Arnold DL. Segmentation of magnetization transfer ratio lesions for longitudinal analysis of demyelination and remyelination in multiple sclerosis. Neuroimage. 2012;66C:103-9.
148. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol. 2002;23:985-8.
149. Rashid W, Davies GR, Chard DT, Griffin CM, Altmann DR, Gordon R, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3Â year study. J Neurol Neurosurg Psychiatry. 2006;77:51-5.
150. Mcguigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117-25.
151. Schwab N, Schneider-Hohendorf T, Pignolet B, Breuer J, Gross CC, Göbel K, et al. Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values. Neurol Neuroimmunol Neuroinflammation. 2016;3:e195.
152. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865-71.
153. Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, Görlich D, Meinl I, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2015. doi: 10.1177/1352458515607651.
154. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol. 2014;176:149-64.
155. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm. 2015;2:e62.
156. Kim S-M, Woodhall MR, Kim J-S, Kim S-J, Park KS, Vincent A, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm. 2015;2:e163.
157. Zekeridou A, Lennon VA. Aquaporin-4 autoimmunity. Neurol Neuroimmunol Neuroinflamm. 2015;2:e110.